FIND Study Shows Cepheid TB Test Performs Well in Remote Labs, Reduces Time to Treatment | GenomeWeb

By Ben Butkus

Cepheid's PCR-based test for tuberculosis and rifampicin resistance has received another clinical endorsement for its ability to perform in remote and resource-poor regions of the world, according to a research study published this week.

The positive findings were published in the same week that Cepheid reported strong first-quarter results and several financial analysts raised their earnings estimates and price targets for the company.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.